FDA Committee Casts Negative Vote on Sotagliflozin in Type 1 Diabetes – MD Magazine

Facebook Twitter Pinterest LinkedIn People lost substantially more weight when they took Eli Lilly’s diabetes drug Mounjaro than Novo Nordisk’s Ozempic, with roughly the same side effects, drop-out rate and benefit for diabetes, according to the first major head-to-head study. Both drugs are in the same class, known as GLP-1s, but Lilly’s drug, tirzepatide, sold…